{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T17:36:17Z","timestamp":1787160977745,"version":"build-2736575974"},"reference-count":20,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"16","content-domain":{"domain":["www.ahajournals.org"],"crossmark-restriction":true},"short-container-title":["JAHA"],"published-print":{"date-parts":[[2026,8,18]]},"abstract":"<jats:sec xml:lang=\"en\">\n                    <jats:title>Background<\/jats:title>\n                    <jats:p xml:lang=\"en\">Prognostic staging systems in transthyretin amyloid (ATTR) cardiomyopathy were developed before the introduction of disease\u2010modifying treatment. We therefore evaluated contemporary risk stratification according to different staging systems in patients with ATTR cardiomyopathy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec xml:lang=\"en\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p xml:lang=\"en\">All patients with newly diagnosed ATTR cardiomyopathy and baseline biomarker measurements from 2019 to 2023 were included from Mayo Clinic, Rochester, MN. Prognostic outcomes were calculated with Kaplan\u2013Meier analysis for 3e staging systems in the main analysis: the National Amyloidosis Centre (NAC) staging system; a modified Mayo staging system using hsTNT (high\u2010sensitivity troponin T) cutoff &gt;65 ng\/L; the extended NAC model with a fourth stage (NT\u2010proBNP [N\u2010terminal pro\u2010B\u2010type natriuretic peptide] &gt;10\u2009000 ng\/L).<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec xml:lang=\"en\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p xml:lang=\"en\">The study population consisted of 441 patients with a median age of 76\u2009years, 93% were men, 85% were initiated on tafamidis, and 94% had wild\u2010type ATTR. Median follow\u2010up was 3.4\u2009years, and 109 deaths occurred during follow\u2010up. The 3\u2010year survival for the Mayo stages were 92.3% (88.7\u201395.9) for stage I, 71.6% (63.0\u201381.3) for stage II, and 43.5% (32.4\u201358.5) for stage III. For the NAC system, 3\u2010year survival were 92.0% (89.0\u201395.7), 67.5% (59.0\u201377.3), and 47.0% (34.7\u201363.5) for stages I, II, and III, respectively.<\/jats:p>\n                    <jats:p xml:lang=\"en\">The 3\u2010year survival by the extended NAC system was 92.0 (69.0\u201379.2), 69.0% (60.1\u201379.2), 53.2% (39.9\u201370.8) and 34.4% (17.4\u201368.0) for stages I, II, III, and IV, respectively.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec xml:lang=\"en\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p xml:lang=\"en\">In a contemporary cohort of patients with ATTR cardiomyopathy, the NAC and modified Mayo staging systems remained equally effective in delineating clinically meaningful prognostic groups, whereas the extended NAC system identified a stage IV subgroup with high mortality.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1161\/jaha.125.048585","type":"journal-article","created":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T03:41:11Z","timestamp":1786160471000},"update-policy":"https:\/\/doi.org\/10.1161\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Utility of Prognostic Staging Systems in Transthyretin Amyloidosis Cardiomyopathy in the Era of Available Disease\u2010Modifying Treatment"],"prefix":"10.1161","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9048-690X","authenticated-orcid":false,"given":"Jens K.","family":"Skov","sequence":"first","affiliation":[{"name":"Aarhus University and Aarhus University Hospital","place":["Aarhus N, Denmark"]},{"name":"Aarhus University and Aarhus University Hospital","place":["Aarhus N, Denmark"]},{"name":"Aarhus University Hospital","place":["Aarhus N, Denmark"]},{"name":"G\u00f8dstrup Regional Hospital","place":["Herning, Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6042-6404","authenticated-orcid":false,"given":"Tor S.","family":"Clemmensen","sequence":"additional","affiliation":[{"name":"Aarhus University and Aarhus University Hospital","place":["Aarhus N, Denmark"]},{"name":"Aarhus University Hospital","place":["Aarhus N, Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1340-0647","authenticated-orcid":false,"given":"Christopher G.","family":"Scott","sequence":"additional","affiliation":[{"name":"Mayo Clinic","place":["Rochester, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3256-3660","authenticated-orcid":false,"given":"Omar F.","family":"Abou Ezzedine","sequence":"additional","affiliation":[{"name":"Mayo Clinic","place":["Rochester, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian C.","family":"Chang","sequence":"additional","affiliation":[{"name":"Mayo Clinic","place":["Rochester, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8780-9512","authenticated-orcid":false,"given":"Angela","family":"Dispenzieri","sequence":"additional","affiliation":[{"name":"Mayo Clinic","place":["Rochester, USA"]},{"name":"Mayo Clinic","place":["Rochester, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steen H.","family":"Poulsen","sequence":"additional","affiliation":[{"name":"Aarhus University and Aarhus University Hospital","place":["Aarhus N, Denmark"]},{"name":"Aarhus University Hospital","place":["Aarhus N, Denmark"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2541-4440","authenticated-orcid":false,"given":"Martha","family":"Grogan","sequence":"additional","affiliation":[{"name":"Mayo Clinic","place":["Rochester, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"e_1_3_2_2_2","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.0442"},{"key":"e_1_3_2_3_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehab072"},{"key":"e_1_3_2_4_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchf.2020.03.007"},{"key":"e_1_3_2_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2019.11.006"},{"key":"e_1_3_2_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehx589"},{"key":"e_1_3_2_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2016.06.033"},{"key":"e_1_3_2_8_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2019.12.020"},{"key":"e_1_3_2_9_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacadv.2024.101568"},{"key":"e_1_3_2_10_2","doi-asserted-by":"publisher","DOI":"10.1002\/ejhf.3354"},{"key":"e_1_3_2_11_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1805689"},{"key":"e_1_3_2_12_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIR.0000000000000792"},{"key":"e_1_3_2_13_2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2018-10-875252"},{"key":"e_1_3_2_14_2","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-145-4-200608150-00004"},{"key":"e_1_3_2_15_2","doi-asserted-by":"crossref","unstructured":"Accessed April 2025. http:\/\/www.accurint.com.","DOI":"10.46576\/djtechno.v6i1.6404"},{"key":"e_1_3_2_16_2","doi-asserted-by":"publisher","DOI":"10.1093\/biomet\/92.4.965"},{"key":"e_1_3_2_17_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2024.12.005"},{"key":"e_1_3_2_18_2","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.118.038169"},{"key":"e_1_3_2_19_2","doi-asserted-by":"publisher","DOI":"10.1053\/j.ajkd.2023.04.002"},{"key":"e_1_3_2_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2020.100662"},{"key":"e_1_3_2_21_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2020.06.007"}],"container-title":["Journal of the American Heart Association"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ahajournals.org\/doi\/full\/10.1161\/JAHA.125.048585","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,19]],"date-time":"2026-08-19T16:33:35Z","timestamp":1787157215000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ahajournals.org\/doi\/10.1161\/JAHA.125.048585"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,18]]},"references-count":20,"journal-issue":{"issue":"16","published-print":{"date-parts":[[2026,8,18]]}},"alternative-id":["10.1161\/JAHA.125.048585"],"URL":"https:\/\/doi.org\/10.1161\/jaha.125.048585","relation":{},"ISSN":["2047-9980"],"issn-type":[{"value":"2047-9980","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,18]]},"assertion":[{"value":"2026-01-24","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-09","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-07","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e048585"}}